Clene Inc.
NASDAQ:CLNNBiotechnology
+$0.08 today
- Market cap
- $52.70M
- Beta
- 0.92
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$2.88
Volume 0.12M
Average 0.50M
CLNN Sales of Investments
Cash received from selling or redeeming investments.
Clene Inc.NASDAQ: CLNN
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments outflow grows to $0
Q1 FY2026 sales of investments was $0, compared with $0 a year earlier. Trailing-twelve-month sales of investments was $0.
Context
- Sales of investments amounted to 0.0% of revenue in FY2025, down 3655.0 pp from a year earlier.
- Sales of investments increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly sales of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 12.5M | +150.0% |
| FY2023 | 2023-12-31 | 5M | -74.5% |
| FY2022 | 2022-12-31 | 19.63M | — |
| FY2021 | 2021-12-31 | 0 | — |
Sales of Investments vs competitors
How CLNN compares with its peers on the latest reported figures
- CLNN's LTM Mar 2026 sales of investments of $0 is the 9th largest of the 11 companies compared; the peer median is $51.88M.
- Its year-over-year change of -100.0% is the lowest of 9, against a peer median of -6.6%.
- Sales of investments amounts to 0.0% of revenue for CLNN, versus a peer median of 713.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $315.09M | -3.2% | +24.0% | — | |
| LTM Mar 2026 | $270.41M | -7.7% | -13.8% | — | |
| LTM Mar 2026 | $125.44M | -4.7% | -21.0% | 79.9% | |
| LTM Mar 2026 | $81.13M | -49.2% | -19.4% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $59.85M | -5.5% | +67.4% | 837.6% |
| LTM Mar 2026 | $43.92M | -54.1% | -43.1% | 4391.5% | |
| LTM Mar 2026 | $42M | -61.1% | -22.4% | 589.7% | |
| FY2025 | $39.95M | +216.4% | +5.0% | 62417.2% | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding CLNN) | $51.88M | -6.6% | -16.6% | 713.7% | |
Competitors are the stored peer set for CLNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.74M) | (29.92M) | (49.5M) | (39.4M) | (26.17M) |
| Depreciation & Amortization | 955K | 1.02M | 1.71M | 1.65M | 1.5M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 12.38M | 8.51M | 9.12M | 7.95M | 6.38M |
| Change in Working Capital | 1M | (1.54M) | (191K) | 3.21M | (3.35M) |
| Accounts Receivables | (28K) | (140K) | 46K | 79K | 64K |
| Inventory | 150K | (2K) | 6K | (31K) | 31K |
| Accounts Payables | 1.27M | 285K | (1.51M) | (264K) | (348K) |
| Other Working Capital | (386K) | (1.68M) | 1.27M | 3.43M | (3.1M) |
| Other Non-Cash Items | (39.23M) | (17.09M) | 8.7M | 5.27M | 3.1M |
| Operating Cash Flow | (34.62M) | (39.01M) | (30.17M) | (21.33M) | (18.55M) |
| Capital Expenditures | (1.33M) | (5.18M) | (330K) | (15K) | (39K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (24.61M) | (6.17M) | (6.17M) | 0 |
| Sales of Investments | 0 | 19.63M | 5M | 12.5M | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.33M) | (10.16M) | (1.5M) | 6.32M | (39K) |
| Debt Repayment | 19.84M | 5.56M | 269K | (10.9M) | 1.12M |
| Common Stock Issued | 9.25M | 11.46M | 42.09M | 9.24M | 10.4M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.98M) | 229K | (200K) | 124K | 0 |
| Financing Cash Flow | 27.11M | 17.25M | 42.16M | (1.53M) | 11.52M |
| Effect of Forex Changes | (85K) | (30K) | (4K) | (127K) | 101K |
| Net Change in Cash | (8.93M) | (31.96M) | 10.49M | (16.67M) | (6.97M) |
| Free Cash Flow | (35.96M) | (44.19M) | (30.5M) | (21.34M) | (18.59M) |
Clene Inc.
NASDAQ:CLNN
Intrinsic Alpha fair value
Locked
Current Price
$3.66
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.